EP0594813A1 - Nouvelle piperazine d'aminoalkyle et d'iminoalkyle - Google Patents

Nouvelle piperazine d'aminoalkyle et d'iminoalkyle

Info

Publication number
EP0594813A1
EP0594813A1 EP93909109A EP93909109A EP0594813A1 EP 0594813 A1 EP0594813 A1 EP 0594813A1 EP 93909109 A EP93909109 A EP 93909109A EP 93909109 A EP93909109 A EP 93909109A EP 0594813 A1 EP0594813 A1 EP 0594813A1
Authority
EP
European Patent Office
Prior art keywords
group
compound
hydrogen atom
general formula
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93909109A
Other languages
German (de)
English (en)
Inventor
Stefan Bengtsson
Lennart Florvall
Gerd Hallnemo
David Jackson
Svante Ross
Bo-Ragnar Tolf
Bengt Ulff
Lian Zhang
Christina KESSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Publication of EP0594813A1 publication Critical patent/EP0594813A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C07D209/66—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Definitions

  • the present invention relates to novel, 1-aryl-4( ⁇ -amido-1-alkyl and ⁇ -imido-1-alkyl)piperazines, intermediates and processes for their preparation, pharmaceutical compositions containing the piperazines and to the use of said compounds in therapy.
  • the object of the present invention is to provide novel compounds that will be useful in the treatment of psychiatric disorders such as schizophrenia and other psychoses, anxiety, depression and manic-depressive psychosis.
  • R is a hydrogen atom or a phenyl group
  • m is an integer 3 to 8
  • R 4 is situated in the meta or para position of the ring and represents an NO 2 -group or a group NR 7 R 8 wherein R 7 and R 8 are the same or different and each represents a hydrogen atom or an alkyl group having 1-3 carbon atoms,
  • R 5 is situated in the ortho, meta or para position and represents a hydrogen atom, a halogen atom, or CF 3 ,
  • R 6 is situated in the ortho, meta or para position and represents a halogen atom or CF 3
  • W is an optionally substituted aromatic ring(s), a heterocyclic ring, a carbocyclic ring(s), or an optionally substituted methylene group
  • A is a hydrogen atom, a hydroxy group, a halogen atom, CF 3 , an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, a phenyl group, or a phenoxy group,
  • B is a hydrogen atom
  • a and B together constitute a carbonyl group, n 1 is 0 or 1, and n 2 is 0 or 1, in racemic or optically active form, or as a mixture of diastereomers, provided that 1) when W is an optionally substituted aromatic ring(s) then
  • R, m, R 4 , R 5 , and Rg are as defined above,
  • n 1 is 0 or 1
  • n 2 is 0 or 1
  • A is a hydrogen atom, a halogen atom, CF 3 , a hydroxy group, an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, a phenyl group, or a phenoxy group, and
  • B is a hydrogen atom
  • R, m, R 4 , R 5 , and R 6 are as defined above,
  • n 1 is 0 or 1
  • n 2 is 0 or 1
  • a and B are hydrogen atoms or A and B together constitute a carbonyl group
  • R, m, R 4 , R 5 , and R 6 are as defined above,
  • n 1 and n 2 are 1 or
  • n 1 is 1 and n 2 is 0 or
  • An aromatic ring(s) in the definition above is preferably phenyl or naphthyl and is mono- or disubstituted, wherein the substituents are preferably chosen from the following: a hydrogen atom, a halogen atom, a hydroxy group, CF 3 , an alkyl group (s) having 1-3 carbon atoms, or an alkoxy group (s) having 1-3 carbon atoms.
  • Heterocyclic ring in the definition above is preferably furyl, thienyl, pyrrolyl, pyridyl, or indolyl.
  • a carbocyclic ring(s) in the definition above is preferably mono, bi, or polycyclic rings having 3-12 carbon atoms.
  • the substituents on the carbocyclic ring(s) in the definition above are preferably a hydrogen atom or an alkyl group having 1-3 carbon atoms.
  • the substituent on the methylene group in the definition above is preferably a hydrogen atom or an alkyl group having 1-4 carbon atoms.
  • Halogen in the definition above is preferably a chlorine, bromine, or fluorine atom.
  • R 1 is situated in the 3- or 4-position and represents a hydrogen atom, a halogen atom, CF 3 , an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, NO 2 , COCH 3 , or NR 2 R 3 wherein R 2 and R 3 are the same or different and each represents a hydrogen atom or an alkyl group having 1-6 carbon atoms, m is an integer 3 to 8,
  • R 4 is situated in the meta or para position of the ring and represents an NO 2 group or a group NR 7 R 8 wherein R 7 and R 8 are the same or different and each represents a hydrogen atom or an alkyl group having 1-3 carbon atoms,
  • R 5 is situated in the ortho, meta, or para position of the ring and represents a hydrogen atom, a halogen atom, or CF 3
  • R 6 is situated in the ortho, meta, or para position of the ring and represents a halogen atom or CF 3
  • W is preferably chosen from the following groups : the substituents preferably being a halogen atom, a hydroxy group, or a methoxy group, mcst preferred are bromine, hydroxy, or methoxy in the ortho and/or meta positions.
  • m is preferably 4-6
  • R 4 is preferably NH 2 ,
  • R 4 is NH 2 in the meta or para positions
  • R 5 is preferably hydrogen or halogen
  • R 5 is hydrogen, chlorine, or bromine
  • R 5 are hydrogen or chlorine in the meta or para positions
  • R 6 is preferably CF 3 or halogen
  • R 6 is CF 3 or chlorine
  • R 6 are CF 3 or chlorine in the meta position.
  • R is preferably H.
  • n 1 is preferably 0 and n 2 is preferably 0 or 1, most preferred n 2 is 0,
  • A is preferably hydrogen, methoxy, or hydroxy in the ortho position.
  • n 1 is preferably 0.
  • n 1 is preferably 0,
  • A is preferably a hydrogen atom or an alkyl group with 1- 3 carbon atoms
  • W is viii, then
  • n 1 and n 2 are preferably 0 and
  • a and B preferably constitute a carbonyl group.
  • n 1 and n 2 are preferably 1 and
  • a and B preferably constitute a carbonyl group
  • n 1 and n 2 are preferably 0 and
  • a and B preferably constitute a carbonyl group
  • Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compounds of this invention.
  • Illustrative acids are sulfuric, nitric, phosphoric, oxalic, hydrochloric, formic, hydrobromic, citric, acetic, lactic, tartaric, pamoic, ethanedisulfonic, sulfamic, succinic, propionic, glycollic, malic, mandelic acid, gluconic, pyruvic, phenylacetic, 4-aminobenzoic, anthranilic, salicylic, 4-aminosalicylic, 4-hydroxybenzoic, nicotinic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, benzenesulfonic, p-toluenesulfonic, sulfanilic, naphthalenesulfonic, ascorbic, cyclohexyl
  • R is a hydrogen atom or a phenyl group
  • m is an integer 3 to 8
  • R 4 is situated in the meta or para position of the ring and represents an NC 2 -group or a group NR 7 R 8 wherein R 7 and R 8 are the same or different and each represents a hydrogen atom or an alkyl group having 1-3 carbon atoms,
  • R 5 is situated in the ortho, meta or para position and represents a hydrogen atom, a halogen atom, or CF 3 ,
  • R 6 is situated in the ortho, meta or para position and represents a halogen atom, or CF 3 ,
  • W is an optionally substituted aromatic ring(s), a heterocyclic ring, a carbocyclic ring(s), or an optionally substituted methylene group,
  • A is a hydrogen atom, a hydroxy group, a halogen atom, CF 3 , an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, a phenyl group, or a phenoxy group,
  • B is a hydrogen atom, or A and B together constitute a carbonyl group, n 1 is 0 or 1, and n 2 is 0 or 1, in racemic or optically active form, or as a mixture of diastereomers, provided that 1) when W is an optionally substituted aromatic ring(s) then
  • R, m, R 4 , R 5 , and R 6 are as defined above,
  • n 1 is 0 or 1
  • n 2 is 0 or 1
  • A is a hydrogen atom, a halogen atom, CF 3 , a hydroxy group, an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, a phenyl group, or a phenoxy group and
  • B is a hydrogen atom
  • R, m, R 4 , R 5 , and R 6 are as defined above,
  • n 1 is 0 or 1
  • n 2 is 0 or 1
  • a and B are hydrogen atoms or
  • a and B together constitute a carbonyl group, 3) when W is an optionally substituted methylene group then
  • R, m, R 4 , R 5 , and R 6 are as defined above, n 1 and n 2 are 1 or
  • n 1 is 1 and n 2 is 0 or
  • a and B together constitute a carbonyl group are prepared by any of the following alternative methods
  • R, m, W, A, B, n 1 and n 2 are as defined above and X is a suitable leaving group such as halogen, arylsulfonate or alkylsulfonate, with a compound of the general formula III
  • R 4 , R 5 and R 6 are as defined above in a suitable solvent, such as an alcohol, DMF, acetonitrile or DMSO in the presence of a base such as triethylamine, sodium hydroxide, or potassium carbonate and a catalytic amount of a sodium or potassium halide, such as KI at ambient or higher temperature for a prolonged time.
  • a suitable solvent such as an alcohol, DMF, acetonitrile or DMSO
  • a base such as triethylamine, sodium hydroxide, or potassium carbonate
  • a catalytic amount of a sodium or potassium halide such as KI at ambient or higher temperature for a prolonged time.
  • R, m, R 5 , R 6 , W, A, B, n 1 and n 2 are as defined above and Y is situated in the meta or para position and represents a group which can be transformed to a group R 4 , where R 4 is situated in the meta or para position of the ring and represents a group NR 7 R 8 , wherein R 7 and R 8 are as defined above, by a suitable hydrolytic, reductive, electrochemical or other known processes.
  • Compounds of the formula IV can be prepared according to Method A.
  • Such a group Y may be chosen from easily cleaved amides, carbamates, imines, benzylic amines or other suitably protected amino groups.
  • Such groups can be trifluoroacetamido, formamido, t-butoxycarbonylamino, or N-benzylamino .
  • Y can be a group such as nitro, azido, hydroxyamino, hydrazono, amido or imino, which can be transformed to R 4 1 by known reductive processes.
  • R, m, W, A, B, n 1 and n 2 are as defined above and Z is hydrogen, hydroxy, halogen, or alkoxy, with a compound of the general formula III
  • R 4 , R 5 and R 6 are as defined above in the presence of a suitable reducing agent such as sodium cyanoborohydride or lithium aluminium hydride in a direct or stepwise manner.
  • a suitable reducing agent such as sodium cyanoborohydride or lithium aluminium hydride in a direct or stepwise manner.
  • W, n 1 , n 2 , and A are as defined above, and T independently or together with A represents a suitable derivative of an aliphatic, cycloaliphatic, aromatic or heterocyclic acid or acid derivative, such as a halide, an ester, an imide, an anhydride, or other acid activating group, with a compound of the general formula VII
  • m, R 4 , R 5 and R 6 are as defined above, in a suitable solvent such as dichloromethane, chloroform, toluene, acetic acid, or tetrahydrofuran or neat at ambient or elevated temperature for a prolonged time.
  • a suitable solvent such as dichloromethane, chloroform, toluene, acetic acid, or tetrahydrofuran or neat at ambient or elevated temperature for a prolonged time.
  • R, m, R 4 , W, A, B, n 1 and n 2 are as defined above and R 5 is H, halogen, or CF 3 with a suitable halogenating reagent such as sulfuryl chloride, or bromine in a suitable solvent such, as chloroform or dioxane.
  • a suitable halogenating reagent such as sulfuryl chloride, or bromine in a suitable solvent such, as chloroform or dioxane.
  • W, n 1 and n 2 are as defined above, A and B together represent a carbonyl group, and M represents a suitable alkali metal such as sodium or potassium, with a compound of the general formula X
  • X, R 4 , R 5 and R 6 are as defined above in a suitable solvent such as DMF, acetonitrile, or DMSO in the presence of a base such as triethylamine, sodium hydroxide, or potassium carbonate at ambient or higher temperature for a prolonged time.
  • a suitable solvent such as DMF, acetonitrile, or DMSO
  • a base such as triethylamine, sodium hydroxide, or potassium carbonate
  • a compound of the general formula II wherein R, m, W, A, B, n 1 , n 2 and X are as defined above, can be prepared by reacting a compound of the general formula VI
  • W, n 1 , n 2 , and A are as defined above, and T independently or together with A represents a suitable derivative of an aliphatic, cycloaliphatic, aromatic or heterocyclic acid or acid derivative, such as a halide, an ester, an imide, an anhydride, or other acid activating group, with a compound of the general formula XI
  • R, m, W, A, B, n 1 and n 2 are as defined above, with a suitable halogenating agent such as thionyl chloride, phosgene, oxalyl chloride, or phosphorous tribromide, or with a suitable sulfonating agent such as tosyl chloride or other arylsulfonyl chloride or alkylsulfonyl chloride.
  • a suitable halogenating agent such as thionyl chloride, phosgene, oxalyl chloride, or phosphorous tribromide
  • a suitable sulfonating agent such as tosyl chloride or other arylsulfonyl chloride or alkylsulfonyl chloride.
  • R 4 1 , R 5 and R 6 are as defined above can be prepared from a compound of the general formula XIII
  • R 5 and R 6 are as defined above and Y is NO 2 can be prepared by reacting a compound of the general formula XIV
  • R 5 and R 6 are as defined above, Y is NO 2 and U is a halogen, with piperazine or a suitably monosubstituted piperazine, where the substituent is easily removeable, such as a benzyl or an ethoxycarbonyl group,
  • X is as defined above and V is hydrogen or an easily removable group such as benzyl or ethoxycarbonyl.
  • the compounds of the formula I will normally be administered orally, rectally or by injection, in the form of pharmaceutical preparations comprising the active ingredient either as a free base or a pharmaceutically acceptable non-toxic, acid addition salt, e.g. the hydrochloride, hydrobromide, lactate, acetate, phosphate, sulfate, sulfamate, citrate, tartrate, oxalate and the like in association with a pharmaceutically acceptable dosage form.
  • the dosage form may be a solid, semisolid or liquid preparation.
  • the active substance will constitute between 0.1 and 99 % by weight of the preparation, more specifically between 0.5 and 20 % by weight for preparations intended for injection and between 0.2 and 50 % by weight for preparations suitable for oral administration.
  • the selected compound may be mixed with a solid excipient, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets.
  • a concentrated sugar solution which may contain, e.g.
  • the tablet can be coated with a polymer well known in the art, dissolved in a readily volatile organic solvent or mixture of organic solvents or in water. Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances or different amounts of the active compounds.
  • the active substance may be admixed with e.g. a vegetable oil or polyethylene glycol.
  • Hard gelatine capsules may contain granules of the active substance using either the above mentioned excipients for tablets e.g. saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose derivatives or gelatine. Also liquids or semisolids of the drug can be filled into hard gelatine capsules.
  • Dosage units for rectal application can be solutions or suspensions or can be prepared in the form of suppositories comprising the active substance in admixture with a neutral fatty base, or gelatine rectal capsules comprising the active substance in admixture with vegetable oil or paraffin oil.
  • Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing from about 0.2 % to about 20 % by weight of the active substance herein described, the balance being sugar and mixture of ethanol, water, glycerol, and propylene glycol.
  • Such liquid preparations may contain colouring agents, flavouring agents, saccharin and carboxymethylcellulose as a thickening agent or other excipients well known in the art .
  • Solutions for parenteral applications can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substance preferably in a concentration of from about 0.5 % to about 10 % by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules .
  • Suitable daily doses of the compounds of the invention in the therapeutic treatment of humans are 50 - 500 mg by oral administration and up to 100 mg via parenteral administration.
  • Example 4 1-(4-Amino-3-trifluoromethylphenyl) -4-[4-(4-chlorophthalimido)-1-butyl]piperazine dihydrochloride.
  • Example 18 1-(4-Amino-3-methylphenyl)-4-(4-phthalimido-1-butyl)-piperazine acetate.
  • Example 13 The product in Example 13 (1.0 g, 2 mmol) was dissolved in 20 ml dioxane and 5 ml methanol. Bromine (350 mg, 2.2 mmol) dissolved in 3 ml dioxane was added and the mixture stirred at ambient temperature for 5 hours, the solvent evaporated, the residue made alkaline with 2 M aqueous NaOH and extracted with methylene chloride. The solvent was removed and the residue dissolved in diisopropyl ether and a precipitate of the title compound was obtained with oxalic acid dissolved in ethanol.
  • the residual acid chloride was dissolved in 20 ml dichloromethane and added to a solution of 5-aminopentanol (1.8 g, 18 mmol) and triethylamine (4 ml, 28 mmol) in 30 ml dichloromethane at -35oC and the temperature allowed to rise to 0oC in 4 h.
  • the solution was washed with dilute HCl, the organic phase separated, and the solvent removed to yield 2.2 g of a crude oil.
  • This oil was dissolved in 20 ml dichloromethane, triethylamine (4 ml, 28 mmol) and tosylchloride (1.33 g, 7 mmol) were added, and the mixture was stirred at ambient temperature overnight.
  • compositions to be used in the method of the invention.
  • preparation of tablets the following compositions can be made.
  • compositions 1 000 tablets can be made, containing 50 mg and 100 mg of active substance, respectively. If desired, the obtained tablets can be film coated with e.g. hydroxypropyl methyl cellulose in an organic solvent or using water.
  • Tissue preparation The rats are decapitated and the striata dissected out on ice.
  • the tissue is homogenized at 0oC in 20 ml 0.05 M Tris-HCl buffer pH 7.7, using a Branson B30 sonifier.
  • the homogenate is centrifuged at 4oC for 10 minutes at 48000 g, in a Sorvall RC-5B Refrigerated Superspeed Centrifuge. The pellet is resuspended and recentrifuged.
  • the final pellet is resuspended in incubation buffer (0.05 M Tris-HCl pH 7.6 containing 0.1% ascorbic acid, 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 and 10 ⁇ M pargylin), to a final concentration of 2.5 mg wet weight/0.5 ml.
  • incubation buffer 0.05 M Tris-HCl pH 7.6 containing 0.1% ascorbic acid, 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 and 10 ⁇ M pargylin
  • Receptor binding assay Various concentrations of the test compound, the radioligand (InM H-Raclopride) and the homogenate are incubated for 60 min at room temperature. Non-specific binding is determined by the addition of 1 ⁇ M (+)-Butaclamol. The incubation is terminated by rapid filtration through glass fiber paper (Whatman GF/B) and subsequent washing with cold incubation buffer, using a cell harvester equipment. The radioactivity of the filters is measured in a Packard 2200CA liquid scintillation counter. Data is analyzed by non-linear regression using the LIGAND program, and presented as Ki values.
  • the incubation mixture (2 ml) contained 3 H-8-OH-DPAT (0.25 to 8 nM), 5 mg/ml tissue homogenate in 50 mM Tris-HCl buffer containing 4.0 mM CaCl 2 and 5.7 mM ascorbic acid, pH 7.5.
  • 6 different concentrations of 3 H-8-OH-DPAT were analyzed. Binding experiments were started by the addition of tissue homogenate and followed by incubation at 37oC for ten min.
  • the incubation mixtures were filtered through Whatman GF/B glass filters with a Brandel Cell Harvester (Gaithersburgh, MD, USA).
  • the filters were washed twice with 5 ml ice-cold 50 mM Tris-HCl buffer, pH 7.5, and counted with 5 ml Ultima GoldTM (Packard) in a Beckman LS 3801 scintillation counter. Non-specific binding was measured by the addition of 10 ⁇ M 5-HT to the reaction mixture.
  • the binding data were processed by non-linear least squares computer analysis (Munson and Rodbard, Anal. Biochem. 107, 220-239, (1980). Data were presented as K i values (nM).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

Composé représenté par la formule générale (I) dans laquelle R représente un atome d'hydrogène ou un groupe phényle, m est un entier compris entre 3 et 8, R4 représente un groupe NO2 ou un groupe NR7R8 dans lequel R7 et R8 sont similaires ou différents et chacun représente hydrogène ou alkyle, R5 représente hydrogène, halogène ou CF3, R6 représente halogène ou CF3, W représente un ou des noyaux (x) aromatiques éventuellement substitués, un noyau hétérocyclique, un ou des noyaux carbocyclique ou un groupe méthylène éventuellement substitué, A représente un atome d'hydrogène, un groupe hydroxy, un atome d'halogène, CF3, un groupe alkyle, un groupe alcoxy, un groupe phényle, ou un groupe phenoxy, B représente un atome d'hydrogène ou A et B ensemble constituent un groupe carbonyl, n1 est 0 ou 1 et n2 est 0 ou 1. L'invention décrit également des procédés et des intermédiaires servant à la préparation desdits composés, une préparation pharmaceutique les contenant, ainsi que l'utilisation desdits composés dans le traitement de maladies mentales.
EP93909109A 1992-04-09 1993-04-06 Nouvelle piperazine d'aminoalkyle et d'iminoalkyle Withdrawn EP0594813A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9201138A SE9201138D0 (sv) 1992-04-09 1992-04-09 Novel phthalimidoalkylpiperazines
SE9201138 1992-04-09
PCT/SE1993/000295 WO1993021179A1 (fr) 1992-04-09 1993-04-06 Nouvelle piperazine d'aminoalkyle et d'iminoalkyle
CN93118820A CN1099752A (zh) 1992-04-09 1993-08-31 新型酰氨烷基-和亚氨烷基-哌嗪

Publications (1)

Publication Number Publication Date
EP0594813A1 true EP0594813A1 (fr) 1994-05-04

Family

ID=36869961

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93909109A Withdrawn EP0594813A1 (fr) 1992-04-09 1993-04-06 Nouvelle piperazine d'aminoalkyle et d'iminoalkyle

Country Status (14)

Country Link
EP (1) EP0594813A1 (fr)
JP (1) JPH06508378A (fr)
CN (1) CN1099752A (fr)
AU (1) AU665825B2 (fr)
BG (1) BG98281A (fr)
CA (1) CA2109816A1 (fr)
CZ (1) CZ270193A3 (fr)
FI (1) FI935494L (fr)
HU (1) HUT68891A (fr)
NO (2) NO934426D0 (fr)
SE (1) SE9201138D0 (fr)
SI (1) SI9300191A (fr)
SK (1) SK138993A3 (fr)
WO (1) WO1993021179A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents
GB9411099D0 (en) * 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
FR2742149B1 (fr) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
US5763609A (en) 1996-03-21 1998-06-09 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of gaba brain receptor ligands
US5703235A (en) * 1996-03-21 1997-12-30 Neurogen Corporation N-Aminoalkyl-2-anthracenecarboxamides; new dopamine receptor subtype specific ligands
DK0891344T3 (da) * 1996-04-05 2003-04-07 Sod Conseils Rech Applic Antagonister til alpha-1-adrenergisk receptor
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
CN1665503A (zh) * 2002-07-04 2005-09-07 施瓦茨制药有限公司 杂芳烃甲酰胺作为多巴胺－d3配体用于治疗中枢神经系统疾病的用途
CN1948298B (zh) * 2006-11-09 2010-09-01 东南大学 一种多巴胺d3受体部分激动剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3398151A (en) * 1966-02-01 1968-08-20 Mead Johnson & Co Azaspirodecanediones and azaspiroundecanediones
US3488352A (en) * 1966-10-11 1970-01-06 Shulton Inc Basically substituted alkoxy anthranilamides,their corresponding 2-nitro compounds and derivatives thereof
US3505338A (en) * 1966-11-25 1970-04-07 American Cyanamid Co Thiophenecarbonylalkylene-diamines
FR1537901A (fr) * 1967-07-19 1968-08-30 Bruneau & Cie Lab Dérivés amidés d'acides halogéno et nitro benzoïques et leur préparation
US3558777A (en) * 1968-06-21 1971-01-26 Mead Johnson & Co Pharmacologic processes and compositions containing azaspirodecanediones and azaspiroundecanediones
US3465080A (en) * 1968-10-07 1969-09-02 American Cyanamid Co Therapeutic compositions containing morpholinoalkylene - indoles and methods of administering such in the treatment of depression
JPS504650B2 (fr) * 1971-09-03 1975-02-22
US3940397A (en) * 1974-11-13 1976-02-24 E. R. Squibb & Sons, Inc. 2-[(Substituted-piperazinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones
NL8005133A (nl) * 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
US4361565A (en) * 1981-12-28 1982-11-30 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines
DE3529872A1 (de) * 1985-08-21 1987-02-26 Kali Chemie Pharma Gmbh Neue tetraoxoverbindungen
US4892943A (en) * 1985-10-16 1990-01-09 American Home Products Corporation Fused bicyclic imides with psychotropic activity
IL90279A (en) * 1988-05-24 1995-03-30 American Home Prod Piperazinyl carboxamide derivatives, their preparation and pharmaceutical com¦ositions containing them
DE68918832T2 (de) * 1988-12-28 1995-02-09 Suntory Ltd Benzoxazepinderivate.
US4939137A (en) * 1989-06-28 1990-07-03 Ortho Pharmaceutical Corporation Ring-fused thienopyrimidinedione derivatives
EP0507863A4 (en) * 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5143923B1 (en) * 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9321179A1 *

Also Published As

Publication number Publication date
FI935494A7 (fi) 1993-12-08
SK138993A3 (en) 1994-11-09
BG98281A (en) 1994-09-30
CA2109816A1 (fr) 1993-10-28
NO180794B (no) 1997-03-17
SI9300191A (sl) 1993-12-31
FI935494A0 (fi) 1993-12-08
FI935494L (fi) 1993-12-08
JPH06508378A (ja) 1994-09-22
AU3964393A (en) 1993-11-18
CZ270193A3 (en) 1994-08-17
WO1993021179A1 (fr) 1993-10-28
NO934426L (no) 1993-12-06
NO934426D0 (no) 1993-12-06
AU665825B2 (en) 1996-01-18
SE9201138D0 (sv) 1992-04-09
CN1099752A (zh) 1995-03-08
NO180794C (no) 1997-06-25
HUT68891A (en) 1995-08-28

Similar Documents

Publication Publication Date Title
EP0376607B1 (fr) Dérivés pipérazinoyles
SK119795A3 (en) Indole derivatives as 5-ht1a and/or 5-ht2 ligands
FR2664592A1 (fr) Nouveaux derives de la piperidine, de la tetrahydropyridine et de la pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2655988A1 (fr) Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
SK281457B6 (sk) 3-[4-(4-(4-kyánfenyl)-1-piperazinyl)butyl]-5-kyánindol, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje
US20030083336A1 (en) Phenylpiperazinyl derivatives
EP0594813A1 (fr) Nouvelle piperazine d'aminoalkyle et d'iminoalkyle
EP1246817B1 (fr) Derives de 4-phenyle-1-piperazinyle, -piperidinyle et -tetrahydropyridyle
CA1332835C (fr) Carboxyamides alphatiques
JPH0747585B2 (ja) イソオキサゾール誘導体
US5030639A (en) N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
US5008264A (en) N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
JP2008509962A (ja) ５−ｈｔ７受容体アンタゴニスト
US5166156A (en) Naphthyl piperazines useful as 5-HT1A receptor ligands
FR2731223A1 (fr) Nouveaux derives bi-tryptaminiques, leur procede de preparation et leur utilisation a titre de medicaments
US5472966A (en) Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US4537975A (en) 1-Phenylindazol-3-one compounds
JP2008509961A (ja) ５−ｈｔ７受容体アンタゴニスト
CN101010301A (zh) 5－ht7受体拮抗剂
US5162321A (en) 1-naphthyl piperazines useful as 5-HT1A receptor ligands
SE460419B (sv) Substituerade 1-pyridyloxi-3-indolylalkylamino-2-propanoler, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
US5512566A (en) Tricyclic compounds having affinity for the 5-HT1A receptor
JPS63233972A (ja) 新規なインドールカルボキサミド誘導体及びその塩類、それらの製造法及び中間体、これら誘導体の医薬品への使用並びにそれらを含有する組成物
FR2705344A1 (fr) Dérivés de 2-aminopyrazine-5-carboxamide, leur préparation et leur application en thérapeutique.
CZ284463B6 (cs) N-Substituované azabicykloheptanové deriváty

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHANG, LIAN

Inventor name: ULFF, BENGT

Inventor name: TOLF, BO-RAGNAR

Inventor name: ROSS, SVANTE

Inventor name: JACKSON, DAVID

Inventor name: HALLNEMO, GERD

Inventor name: FLORVALL, LENNART

Inventor name: BENGTSSON, STEFAN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTRA AKTIEBOLAG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971101